Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001553
UniProt IDP52732
Primary gene name(s)KIF11
Synonym gene name(s)EG5, KNSL1, TRIP5
Protein nameKinesin-like protein KIF11
Protein functionMotor protein required for establishing a bipolar spindle during mitosis, PubMed:19001501. Required in non-mitotic cells for transport of secretory proteins from the Golgi complex to the cell surface, PubMed:23857769. {ECO:0000269|PubMed:19001501, ECO:0000269|PubMed:23857769}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:19001501, ECO:0000269|PubMed:23857769}. Cytoplasm, cytoskeleton, spindle pole {ECO:0000269|PubMed:19001501}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P52732
Gene Ontology
(Biological Process)
Complete annatation
antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886];
cell division [GO:0051301];
chromosome segregation [GO:0007059];
microtubule-based movement [GO:0007018];
mitotic centrosome separation [GO:0007100];
mitotic nuclear division [GO:0007067];
mitotic spindle assembly [GO:0090307];
mitotic spindle organization [GO:0007052];
regulation of mitotic centrosome separation [GO:0046602];
retrograde vesicle-mediated transport, Golgi to ER [GO:0006890];
spindle organization [GO:0007051]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
ATP-dependent microtubule motor activity, plus-end-directed [GO:0008574];
microtubule motor activity [GO:0003777];
protein complex binding [GO:0032403];
protein kinase binding [GO:0019901]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
kinesin complex [GO:0005871];
membrane [GO:0016020];
microtubule [GO:0005874];
spindle [GO:0005819];
spindle pole [GO:0000922]
Protein-protein interaction110030
Phylogenetic treeP52732
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.2416276985113760.8266875624991970.882006942322385
AZA vs. DISU0.3225715882762320.4385606721438540.91814655876178
AZA vs. IL70.1179220639275880.7588094201228560.999311006273513
AZA vs. SAHA0.2653816744563530.2901956343439830.662387794079527
DISU vs. CD30.06914541215101970.9489052995786440.966769727228984
DISU vs. IL7-0.2139799695813050.6547156344832180.901215099517406
DISU vs. SAHA-0.0566601962836960.8843514512780750.970078768293724
DMSO vs. AZA-0.09364485186616120.7459062308400771
DMSO vs. CD3-0.3434115804841480.7547251655121280.822954155938058
DMSO vs. DISU-0.4175390904540320.3114452663148070.816178753614525
DMSO vs. IL70.2185674137523990.5643519318853880.902124083852002
DMSO vs. SAHA0.3506890657286530.150631555265610.467786558707605
HIV vs. Mock in Activation0.2906702263929480.8844354122831670.999983755607037
HIV vs. Mock in Latency0.2890939444680750.4031037357580830.999834320637052
IL7 vs. CD3-0.1154957451751990.9154234730661760.946896651765473
SAHA vs. CD3-0.001237316740829940.9990672164666630.999266141378682
SAHA vs. IL70.1437802811686220.6848439340979220.851012485240019
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
3 0.001240307 1.8 0.043882994 2 0.109174897
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.439085 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
0.03 0.003

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.115 1.46 2.202 2.53 1.244
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
-1.2 0.0293 -0.37 0.5408 -0.03 0.7041 DNA recombination; repair and maintenance (4hpi)
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
204444_at 2.41 Yes upregulated in CD4+ cells
204444_at 4.06 Yes upregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB03996 3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol experimental unknown unknown
DB04331 Monastrol experimental unknown unknown
DB07064 (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE experimental unknown unknown
DB08037 (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide experimental unknown unknown
DB08198 [(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE experimental unknown unknown
DB08239 (2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE experimental unknown unknown
DB08244 (1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE experimental unknown unknown
DB08246 (2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE experimental unknown unknown
DB08250 (5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1II6 X-ray 2.1Å A/B=1-368.
1Q0B X-ray 1.9Å A/B=2-368.
1X88 X-ray 1.8Å A/B=10-368.
1YRS X-ray 2.5Å A/B=1-368.
2FKY X-ray 2.3Å A/B=2-368.
2FL2 X-ray 2.5Å A/B=2-368.
2FL6 X-ray 2.5Å A/B=2-368.
2FME X-ray 2.1Å A/B=1-368.
2G1Q X-ray 2.5Å A/B=1-368.
2GM1 X-ray 2.3Å A/B/D/E=1-368.
2IEH X-ray 2.7Å A/B=2-368.
2PG2 X-ray 1.8Å A/B=1-368.
2Q2Y X-ray 2.5Å A/B=2-368.
2Q2Z X-ray 3.0Å A/B=2-368.
2UYI X-ray 2.1Å A/B=1-368.
2UYM X-ray 2.1Å A/B=1-368.
2WOG X-ray 2.0Å A/B/C=1-368.
2X2R X-ray 2.2Å A/B/C=1-368.
2X7C X-ray 1.9Å A/B=1-368.
2X7D X-ray 2.3Å A/B=1-368.
2X7E X-ray 2.4Å A/B=1-368.
2XAE X-ray 2.6Å A/B/C=1-368.
3CJO X-ray 2.2Å A/B=2-368.
3HQD X-ray 2.1Å A/B=1-369.
3K3B X-ray 2.4Å A/B=1-368.
3K5E X-ray 1.9Å A/B=1-368.
3KEN X-ray 2.5Å A=1-369.
3L9H X-ray 2.0Å A/B=1-368.
3WPN X-ray 2.8Å A=1-369.
3ZCW X-ray 1.6Å A=16-363.
4A1Z X-ray 2.8Å A/B=1-368.
4A28 X-ray 2.5Å A/B=1-368.
4A50 X-ray 2.7Å A=1-368.
4A51 X-ray 2.7Å A/B/C/D/E/F/G=1-368.
4A5Y X-ray 2.4Å A/B/C=1-368.
4AP0 X-ray 2.5Å A/B/C/D=1-368.
4AQV EM 9.7Å C=1-367.
4AQW EM 9.5Å C=1-367.
4AS7 X-ray 2.4Å A=1-368.
4B7B X-ray 2.5Å A=1-368.
4BBG X-ray 2.7Å A=1-368.
4BXN X-ray 2.7Å A/B=1-368.
4CK5 EM 10.0Å C=1-367.
4CK6 EM 9.2Å C=1-367.
4CK7 EM 9.2Å C=1-367.
4ZCA X-ray 2.3Å A/B=1-369.
4ZHI X-ray 2.3Å A/B=1-369.
5JV3 X-ray 2.0Å A/B/C/D=366-391.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat modulates 24488929
Tat interacts with 24488929

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found